

[REDACTED]

[REDACTED]

Dtd. Shillong, the 29<sup>th</sup> Aug., 2023

[REDACTED]

Dt. Shillong, the 01.08.23

Sir/Madam,

Kindly find herewith the analytical report of the following Survey Sample of Drugs. This has a reference to the letter cited above.

The details of the report are also enclosed for necessary.

Registration No.	Name of samples	Manufacturer	Batch No.	Mfg. Date	Exp. Date
[REDACTED]	Brufen-200	[REDACTED]	532779D7	05/23	04/26
[REDACTED]	Brufen-400	[REDACTED]	480801D7	12/22	11/25
[REDACTED]	Brufen-400	[REDACTED]	470804D7	11/22	10/25

[REDACTED]

[REDACTED]

Dtd. Shillong, the 29<sup>th</sup> Aug., 2023

Copy to:

[REDACTED]

✓ 2. Managing Director, MMDSL, Department of Health & Family Welfare, DHS Complex, Laitumkhrah, Shillong.

[REDACTED]

Name of the sample and content:

**BRUFEN - 200**

Each film coated tablet contains  
Ibuprofen Erythrosine IP.....200 mg  
Colour: Erythrocin & Titanium Dioxide IP

Manufacturer's name & address:



Date received: **02.08.2023**



Batch No. **532779D7**

Mfg. Date **05/23**

Exp. Date **04/26**

Permitted  
Limits

**Description:** Round film coated tablets, pink in colour with convex surfaces and smooth edges.


**Uniformity of Weights:** Conform to specifications prescribed in IP.

**Identification Tests:** Conform to specifications prescribed in IP.

**Dissolution Test:** % Dissolution of all the tablets taken for the test lies within 90-97 > 75%

**ASSAY:** % Content of active component in sample = 101.08% 95-105%

**REMARKS: SAMPLE PASSED THE TESTS PERFORMED**



Dated: Shillong  
The 29/8/23

Name of the sample and content:

**BRUFEN - 400**

Each film coated tablet contains  
Ibuprofen Erythrosine IP.....400 mg  
Colour: & Titanium Dioxide IP

Manufacturer's name & address:



Date received: **02.08.2023**

REGISTRATION No.



Batch No. **480801D7**

Mfg. Date **12/22**

Exp. Date **11/25**

Permitted  
Limits

**Description:** Round film coated tablets, pink in colour with convex surfaces and smooth edges.


**Uniformity of Weight:** Conform to specifications prescribed in IP.

**Identification:** Conform to specifications prescribed in IP.

**Dissolution:** % Dissolution of all the tablets taken for the test lies within 97-99 > 75%

**ASSAY:** % Content of active component in sample = 103% 95-105%

**REMARKS: SAMPLE PASSED THE TESTS PERFORMED**



Dated: Shillong  
The 29/8/23

Name of the sample and content:

**BRUFEN - 400**

Each film coated tablet contains

Ibuprofen Erythrosine IP.....400 mg

Colour: & Titanium Dioxide IP

Manufacturer's name & address:

Abbott India Ltd.

L-18/19, Verna Industrial Estate

Verna, Salcette, Goa - 403722.

Date received: **02.08.2023**

REGISTRATION No. **DRG/SUR/132/2023**

Batch No. **470804D7**

Mfg. Date **11/22**

Exp. Date **10/25**

Permitted  
Limits

**Description:** Round film coated tablets, pink in colour with convex surfaces and smooth edges.

**Uniformity of Weight:** Conform to specifications prescribed in IP.

**Identification:** Conform to specifications prescribed in IP.

**Dissolution:** % Dissolution of all the tablets taken for the test lies within 96.6-99 > 75%

**ASSAY:** % Content of active component in sample = 103.15% 95-105%

**REMARKS: SAMPLE PASSED THE TESTS PERFORMED**

Dated: Shillong

The 29/8/23

  
Government Analyst  
Drug Testing Laboratory  
Pasteur Institute  
Shillong, Meghalaya  
\*\*\*\*\*